340450 — GC Genome Income Statement
0.000.00%
Last trade - 00:00- KR₩187bn
- KR₩151bn
- KR₩32bn
Annual income statement for GC Genome, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 24,114 | 27,292 | 25,888 | 31,534 |
| Cost of Revenue | ||||
| Gross Profit | 10,765 | 13,697 | 11,707 | 14,628 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 27,349 | 27,132 | 28,247 | 29,745 |
| Operating Profit | -3,236 | 160 | -2,359 | 1,789 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -3,874 | -815 | -1,127 | 4,149 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -3,763 | -550 | -1,257 | 4,044 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -3,763 | -550 | -1,257 | 4,044 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -3,763 | -550 | -1,257 | 4,044 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -159 | -23.3 | -22.3 | 166 |
| Dividends per Share |